By Ramsey Cox
Klobuchar and Grassley’s comments came after the Federal Trade Commission (FTC) released a report Thursday, which showed that the number of potential pay-for-delay agreements rose more than 40 percent this year.
Klobuchar and Grassley said they would reintroduce the Preserve Access to Affordable Generics Act during the 113th Congress to end anti-competitive pay-offs and make sure consumers have access to the cost-saving generic drugs.
“Today’s report shows that pay-for-delay deal-making remains an obstacle to getting cheaper prescription drugs on the market,” Grassley said. “While the Supreme Court will consider a case this year on these deals, Senator Klobuchar and I will continue to press for a legislative remedy to put consumers first.”
Pay-for-delay agreements, or reverse payments, delay generic drug from hitting the market for nearly 17 months on average compared to agreements without payments.